Idiopathic pulmonary fibrosis (IPF) is the most common among idiopathic interstitial pneumonia. Life expectancy is estimated around 3-5 years at diagnosis. No reliable prognostic biomarker has been approved for routinary clinical practice of IPF. The aim of this study is to investigate the potential prognostic value of serum CD59 in a cohort of IPF patients.
Cameli, P., Bergantini, L., D'Alessandro, M., Vietri, L., Cameli, M., Sestini, P., et al. (2021). Serum CD59: a novel biomarker of idiopathic pulmonary fibrosis?. PANMINERVA MEDICA, 63(2), 201-205 [10.23736/S0031-0808.20.03893-8].
Serum CD59: a novel biomarker of idiopathic pulmonary fibrosis?
Cameli, Paolo;Bergantini, Laura;D'alessandro, Miriana;Vietri, Lucia;Cameli, Matteo;Bargagli, Elena
2021-01-01
Abstract
Idiopathic pulmonary fibrosis (IPF) is the most common among idiopathic interstitial pneumonia. Life expectancy is estimated around 3-5 years at diagnosis. No reliable prognostic biomarker has been approved for routinary clinical practice of IPF. The aim of this study is to investigate the potential prognostic value of serum CD59 in a cohort of IPF patients.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento:
https://hdl.handle.net/11365/1106835